Round voting button logo

H.R.1672

Maintaining Investments in New Innovation Act

Introduced·2/27/25

Amends Social Security Act to extend exclusivity period for advanced drug products using genetically targeted technologies.

The Maintaining Investments in New Innovation Act amends title XI of the Social Security Act to extend the exclusivity period for advanced drug products that incorporate genetically targeted technologies. These technologies can modulate gene function. The bill defines an advanced drug product as a drug utilizing such technology. The exclusivity period is extended from 7 to 11 years.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Energy And Commerce Committee
Next
Committee decision

Sponsors

DDDDDD
6
41
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
Democratic CaucusRepublican Caucus

History

Feb 27, 2025

House

Introduced in House

Feb 27, 2025

House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.